A randomized controlled trial from UCLA Health reported that treating insomnia in older adults with cognitive behavioral therapy for insomnia (CBT-I) was linked to both superior sleep outcomes and a slower pace of biological aging on biomarker-based measures. The authors reported that participants assigned to CBT-I were nearly three times as likely to achieve remission of their insomnia compared with those who received sleep-education control. The study used blood-based epigenetic clocks to estimate aging-related changes and found a significant slowing of the pace of aging on the DunedinPACE measure in the CBT-I group.
The trial enrolled nearly 100 adults aged 60 years or older who met DSM-IV criteria for insomnia disorder and were recruited in Los Angeles, CA. Participants were randomized to one of two treatments: an active CBT-I program tailored to insomnia, or a control intervention consisting of sleep education that provided general information about sleep and healthy sleep habits. Blood samples were collected before the 8-week treatment began and again at follow-up visits over the subsequent two years. The investigators compared sleep outcomes and changes in biomarker-based measures of biological aging between the two treatment arms.
To estimate biological aging, researchers applied three established epigenetic measures to the blood samples: DunedinPACE, GrimAge, and PC-PhenoAge. These clocks use DNA methylation patterns to infer aspects of cellular and tissue aging processes rather than simple chronological age. The primary reported finding was that CBT-I was associated with a significant slowing in the pace of biological aging as measured by DunedinPACE. The study did not report that CBT-I reversed aging or made participants biologically younger; rather, it observed a difference in the estimated rate at which biological aging markers progressed.
The lead author, Judith Carroll, PhD, highlighted the practical interpretation offered by the research team: the observed average difference between the CBT-I and control arms on the pace-of-aging metric was −0.02. The investigators interpreted this as indicating that, on average, those in the CBT-I group were aging about 2% slower per year on that biomarker-based measure. The authors cautioned that this metric is challenging to translate directly into concrete clinical outcomes for an individual, but suggested that small per-year differences could become meaningful for long-term health if sustained.
Previous studies have linked insomnia and poor sleep to markers of accelerated biological aging. The article notes hypothesized pathways through which inadequate or disrupted sleep could influence aging-related processes, including dysregulation of stress-response systems, altered metabolism, increased inflammation, and impaired cardiovascular function. Sleep is described as a period when the parasympathetic nervous system predominates and helps the body recover from daytime activity and stressors; persistent sleep disruption may increase sympathetic activity and cellular processes (for example, inflammation and metabolic changes) that contribute to cumulative tissue damage over time. Although the study authors propose that improving sleep might influence these biological systems, they acknowledge that the precise mechanisms connecting improved sleep to changes in epigenetic aging measures remain uncertain.
The article emphasizes that the trial was relatively small, and the authors call for further research before concluding that CBT-I can extend lifespan or prevent age-related disease. While CBT-I produced stronger insomnia remission rates and was associated with a slower epigenetic pace of aging on DunedinPACE, the study does not demonstrate causation for long-term clinical outcomes such as reduced disease incidence or increased survival. The investigators stress the established clinical value of treating insomnia—for symptom relief and improved daytime functioning—and raise the possibility that successful insomnia treatment could also provide broader health protection via effects on biological systems involved in aging. Additional, larger studies with longer follow-up and examination of clinical endpoints are needed to determine whether the observed epigenetic changes translate into reduced age-related morbidity or mortality.
This trial provides preliminary evidence that CBT-I in older adults can both increase rates of insomnia remission and be associated with a modest slowing in an epigenetic marker of the pace of biological aging. The result is hypothesis-generating: it supports further investigation but does not yet establish that treating insomnia will extend lifespan or prevent age-related disease. Clinicians should continue to offer and recommend evidence-based insomnia treatments given their benefits for sleep and daytime functioning, while researchers pursue larger trials and mechanistic studies to clarify potential long-term health impacts.